ALFA-1

UnknownPhase 2, PHASE3

The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate

The Effect of GLP-1 on Postprandial Glucagon Secretion During Prolonged and Intermittent Stimulation of the GLP-1 Receptor Independent of The Gastric Emptying Rate. A Randomized, Open-label Study in People With Type 1 Diabetes

Lead sponsor

Hvidovre University Hospital

Assets

Exenatide / GLP-1 / incretin class catch-all / Liraglutide

Listed sites

Recruiting sites

—

Enrollment

estimated

Study population

Type 1 diabetes

Key I/E criterion

—

Primary endpoint

•Glucagon concentration (postprandial)

Identifiers

Registered as

NCT IDNCT02584582

Org study IDH-3-2014-128

Timeline

Milestones

Study first posted2015-10-22estimated

Last update posted2015-10-22estimated

Study start2015-07 (month precision)

Primary completion2015-11estimated (month precision)

Assets

Investigational agents

Exenatide GLP-1 / incretin class catch-all Liraglutide

Study populations

Who this study enrolls

Type 1 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Type 1 Diabetes

•>18 years

•No residual beta-cell function (stimulated C-peptide < 60 pmol)

Exclusion criteria

•Pancreatitis

•gastroparesis

•history of alcohol and/or drug abuse

•pregnancy and lactation

•other medical or psychological condition that made the patient unsuitable for study participation according to the investigators´ assessment

•contraindications to gastroscopy

•cancer (unless in complete remission > five years)

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Cardiometabolic biomarkers

Glycemic / diabetes

1 endpoint

Secondary/protocol endpoint

Postprandial glucose concentrations

Time frame:4 hours

Postprandial glucose

descriptive, improvement

Cardiometabolic biomarkers

3 endpoints

Secondary/protocol endpoint/low confidence

Ghrelin

Time frame:4 hours

descriptive

Secondary/protocol endpoint

Free fatty acids (FFA)

Time frame:4 hours

Free fatty acids, change

change from baseline, improvement

Secondary/protocol endpoint

triacylglycerol (TAG)

Time frame:4 hours

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Other (unclassified)

8 endpoints

Primary/protocol endpoint/low confidence

Glucagon concentration (postprandial)

Time frame:4 hours

concentration, descriptive

Secondary/protocol endpoint/low confidence

glucagon-like peptide-1 (GLP-1)

Time frame:4 hours

descriptive

Secondary/protocol endpoint/low confidence

glucagon-like peptide-2 (GLP-2)

Time frame:4 hours

descriptive

Secondary/protocol endpoint/low confidence

glucose-dependent insulinotropic polypeptide (GIP)

Time frame:4 hours

descriptive

Secondary/protocol endpoint/low confidence

Cholecystokinin (CCK)

Time frame:4 hours

descriptive

Secondary/protocol endpoint/low confidence

Peptide YY (PYY)

Time frame:4 hours

descriptive

Secondary/protocol endpoint/low confidence

Gastrin

Time frame:4 hours

descriptive

Secondary/protocol endpoint/low confidence

Oxyntomodulin

Time frame:4 hours

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.